Postnonclassical Practices іn the Content of Higher Art Education

The study of the phenomenon of transdisciplinarity in scientific discourse indicates the emergence of a new strategy for solving real practical problems. A new image of post-non-classical science is being formed. However, there are difficulties with the introduction of a transdisciplinary approach into the methodology of musical pedagogical research and with the practical implementation of the methods and techniques of transdisciplinarity. In order to solve this problem, the narrative “We grieved with one grief and rejoiced with one happiness”, based on the life and work of Boris Grinchenko, is presented and analyzed. Pedagogical observations prove that the form of narration created an open atmosphere for the transdisciplinary transfer of pedagogical skills, united the intellectual and creative potential of teachers and students, and proved the expediency of reorienting the musical and pedagogical processes in the context of postnonclassics. Due to a wide inter- and transdisciplinary synthesis, it has become possible to synergistically combine different ways of perceiving and comprehending the unstable and complex world of art

Introduction of Innovative Technologies and Methods of ICT Competency Building of Scientific-Pedagogical Staff Under the COVID-19 Pandemic: Preconditions and Challenges of Future Education System (Ukrainian Experience)

The article considers the problem of the formation of innovative ICT-competence of scientific and pedagogical staff against the background of the implementation of quarantine measures to counteract the COVID-19 epidemic. Particular attention is paid to the content and goals of ICT-competence. The structure of its components is highlighted and the peculiarities of its functioning to ensure research and educational processes during the pandemic and to overcome its consequences are analyzed. Particular attention is paid to the prerequisites for the rapid formation of ICT competence in times of crisis. The features of the process of computerization and digitalization of the academic sphere in the world and Ukraine are analyzed and highlighted. The article analyzes the main trends and vectors of innovative ICT-competence development, notes its current and future goals and objectives

ФОРМИ ЕЛЕКТРОННОГО ПІДПИСУ ТА ОСОБЛИВОСТІ ЙОГО ВИКОРИСТАННЯ В ЗАХИЩЕНИХ ІНФОРМАЦІЙНИХ СИСТЕМАХ

The Law of Ukraine “On Electronic Documents” and “On Electronic Digital Signature”, which came into force on December 28, 2003 and January 1, 2004, respectively, gave the “green light” to the widespread use of electronic documents and digital signatures in the country. Continuation in the introduction of electronic documents, including electronic signature forms and their use in secure information systems, was the adoption in 2018 of the Law of Ukraine "On electronic trust services" (Law of Ukraine "On electronic digital signature" expired) and a number of bylaws regarding electronic interaction between two information resources (state registers / information and telecommunication systems…) and / or for the provision of administrative services. At the same time, the use of the latest technologies aimed at increasing the efficiency of work creates new risks that can lead to the disclosure of sensitive information, the consequences of which can be critical. To prevent this from happening, the system being created or the existing system must be well protected and comply with the Concept of "Secure Information Systems". This Concept includes a number of legislative initiatives, scientific, technical and technological solutions. Also, it is necessary to refer to the definition of a reliable information system, which is provided in the "Orange Book". According to which, a reliable information system is defined as “a system that uses sufficient hardware and software to ensure the simultaneous reliable processing of information of varying degrees of secrecy by different users or groups of users without violating access rights, integrity and confidentiality of data and information, and which maintains its performance under the influence of a set of external and internal threats. " Today, among the established methods of information protection, a special place is occupied by an electronic signature (both for verifying the integrity of the document, confirmation of authorship and for user authentication).«Зелене світло» широкому застосуванню електронних документів та цифрового підпису в державі, дав Закон України «Про електронні документи» та «Про електронний цифровий підпис», які набрали чинності з 28.12.2003 р. і з 01.01.2004 р. відповідно. Продовженням у запровадженні електронних документів, в тому числі, форм електронного підпису та використання їх в захищених інформаційних системах, стало прийняття в 2018 році Закону України «Про електронні довірчі послуги» (Закон України «Про електронний цифровий підпис» втратив чинність) та низки підзаконних актів щодо електронної взаємодії між двома інформаційними ресурсами (державними реєстрами/інформаційно-телекомунікаційними системами) та/або для надання адміністративних послуг. Використання новітніх технологій, спрямованих на збільшення ефективності роботи, водночас породжує нові ризики, які можуть призводити до розкриття чутливої інформації, наслідки чого можуть бути критичними. Щоб цього не трапилося, система що створюється або існуюча система повинні бути добре захищеними та відповідати Концепції «Захищених інформаційних систем». Дана Концепція включає в себе ряд законодавчих ініціатив, наукових, технічних і технологічних рішень. Також, необхідно звернутися і до визначення надійної інформаційної системи, яке надано в «Помаранчевій книзі». Згідно якої, надійна інформаційна система визначається як «система, що використовує достатні апаратні і програмні засоби, щоб забезпечити одночасну достовірну обробку інформації різного ступеня секретності різними користувачами або групами користувачів без порушення прав доступу, цілісності та конфіденційності даних та інформації, і яка підтримує свою працездатність в умовах впливу на неї сукупності зовнішніх і внутрішніх загроз». На сьогодні, серед усталених методів захисту інформації особливе місце займає електронний підпис (як для перевірки цілісності документа, підтвердження авторства так і для автентифікації користувача)

Methodological guidelines of dialogization of cultural and educational practices

The article deals with the methodological ideas of dialogue. It is stated that the dialogue, as a construct of understanding, is within the limits of constructivism to be the basis of the theoretical and methodological support of the spiritual development of a man. The attention is also focused on the functional purpose of the dialogue, namely on its definition as a goal (deliberately chosen image of the intended result) and as a mechanism of transformation of the world that infinitely creates new goals (goalsetting). Everyday dialogical communication outside the philosophical and nonscientific worldview positions of subjects often loses human activity and even makes it impossible for certain productive ways, means and receptions of interaction. In an effort to understand the world and another person, the person always faces new problems that require the abandonment of previous views, so the constructs allow you to gradually move in the world of objects by doing logical operations, interpreting them for mutual understanding

Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance

Membrane overexpression of ErbB-2/HER2 receptor tyrosine kinase (membrane ErbB-2 (MErbB-2)) has a critical role in breast cancer (BC). We and others have also shown the role of nuclear ErbB-2 (NErbB-2) in BC, whose presence we identified as a poor prognostic factor in MErbB-2-positive tumors. Current anti-ErbB-2 therapies, as with the antibody trastuzumab (Ttzm), target only MErbB-2. Here, we found that blockade of NErbB-2 action abrogates growth of BC cells, sensitive and resistant to Ttzm, in a scenario in which ErbB-2, ErbB-3 and Akt are phosphorylated, and ErbB-2/ErbB-3 dimers are formed. Also, inhibition of NErbB-2 presence suppresses growth of a preclinical BC model resistant to Ttzm. We showed that at the cyclin D1 promoter, ErbB-2 assembles a transcriptional complex with Stat3 (signal transducer and activator of transcription 3) and ErbB-3, another member of the ErbB family, which reveals the first nuclear function of ErbB-2/ErbB-3 dimer. We identified NErbB-2 as the major proliferation driver in Ttzm-resistant BC, and demonstrated that Ttzm inability to disrupt the Stat3/ErbB-2/ErbB-3 complex underlies its failure to inhibit growth. Furthermore, our results in the clinic revealed that nuclear interaction between ErbB-2 and Stat3 correlates with poor overall survival in primary breast tumors. Our findings challenge the paradigm of anti-ErbB-2 drug design and highlight NErbB-2 as a novel target to overcome Ttzm resistance.Fil: Cordo Russo, Rosalia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Béguelin, W.. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Díaz Flaqué, María Celeste. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Proietti Anastasi, Cecilia Jazmín. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Venturutti, Leandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Galigniana, Natalia Maricel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Tkach, Mercedes. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Guzmán, P.. Universidad de La Frontera; ChileFil: Roa, J.C.. Universidad de La Frontera; ChileFil: O'Brien, N.A.. David Geffen School of Medicine at UCLA; Estados UnidosFil: Charreau, Eduardo Hernan. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Schillaci, Roxana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Elizalde, Patricia Virginia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentin

Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy

The role of the progesterone receptor (PR) in breast cancer remains a major clinical challenge. Although PR induces mammary tumor growth, its presence in breast tumors is a marker of good prognosis. We investigated coordinated PR rapid and nonclassical transcriptional effects governing breast cancer growth and endocrine therapy resistance.Fil: Díaz Flaqué, María Celeste. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); ArgentinaFil: Galigniana, Natalia Maricel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); ArgentinaFil: Beguelin, Wendy. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); ArgentinaFil: Vicario, Rocio. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); ArgentinaFil: Proietti Anastasi, Cecilia Jazmín. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); ArgentinaFil: Cordo Russo, Rosalia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); ArgentinaFil: Rivas, Martin Alfredo. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); ArgentinaFil: Tkach, Mercedes. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); ArgentinaFil: Guzmán, Pablo. Universidad de la Frontera; ChileFil: Roa, Juan C.. Universidad de la Frontera; ChileFil: Maronna, Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); Argentina. Sanatorio Mater Dei; ArgentinaFil: Pineda, Viviana. Universidad de la Frontera; ChileFil: Muñoz, Sergio. Universidad de la Frontera; ChileFil: Mercogliano, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); ArgentinaFil: Charreau, Eduardo Hernan. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); ArgentinaFil: Yankilevich, Patricio. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigación en Biomedicina de Buenos Aires; ArgentinaFil: Schillaci, Roxana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); ArgentinaFil: Elizalde, Patricia Virginia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); Argentin

Design, synthesis, computational and biological evaluation of new anxiolytics

Abstract New anxiolytics have been discovered by prediction of biological activity with computer programs PASS and DE DEREK for a heterogeneous set of 5494 highly chemically diverse heterocyclic compounds (thiazoles, pyrazoles, isatins, a fused imidazoles and others). The majority of tested compounds exhibit the predicted anxiolytic effect. The most potent activity was found in 2 (4 nitro phenyl) 3 (4 phenylpiperazinomethyl)imidazo[1,2 a]pyridine 8, 1 [(4 bromophenyl) 2 oxoethyl] 3 (1,3 dioxolano) 2 indolinone 3, 5 hydroxy 3 methoxycarbonyl 1 phenylpyrazole 5 and 2 (4 fluorophenyl) 3 (4 methylpiperazinomethyl)imidazo[1,2 a]pyridine 7. The application of the computer assisted approach significantly reduced the number of synthesized and tested compounds and increased the chance of finding new chemical entities (NCEs)

Theoretical Description for Omeprazole Cathodical Electrochemical Determination, Assisted by Omeprazole Electrochemical Determination, Assisted by the Composite Poly(1,2,4-triazole) – VO(OH)

Abstract: In this work, we describe theoretically the possibility of omeprazole electrochemical determination, assisted by the composite containing vanadium oxyhydroxide as an active substance and the polymer of 1,2,4-triazolic derivative as a mediator. The omeprazole molecule undergoes a sulfoxide to sulfide reduction process over a trivalent vanadium compound. The vanadium oxyhydroxide, at its turn, may be oxidized to a tetravalent state, represented in two forms. The electroanalytical process behavior will be illustrated by a trivariate equation-set, analysis of which confirms the efficiency of the composite of poly (1,2,4-triazole) with VO(OH). Vanadium (III) oxyhydroxide may be efficiently used for omeprazole detection both in pharmaceutical formulations, food, and biological liquids

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie